Arthrosi Establishes Joint Venture in China to Accelerate Development of Innovative Drug Portfolio
Arthrosi Therapeutics, Inc. today announced a joint venture in Guangzhou China with Ruiao Biopharmaceutical Technology
Arthrosi Therapeutics, Inc. Announces Impressive Phase 2a Study Results
With AR882 showing strong efficacy and safety profile in Phase 2a study, Arthrosi is accelerating the development and looking to complete the Phase 2
Arthrosi’s New Molecule AR882 for Gout Shows Blockbuster-Potential
Our mission is to eliminate the pain of gout with a new era of gout treatment that provides a true solution. SAN DIEGO
About Us
Arthrosi Therapeutics is a clinical-stage biotech company focused on the development of therapy for gout and chronic kidney disease. Its proprietary drug candidate, AR882, demonstrated unprecedent sustained urate lowering in gout patients and showed potential to treat a variety of renal impaired patients suffering from gout and tophaceous gout..
Arthrosi strives to…
- Create a people-centered environment — you are at the center of everything we do and every decision we make.
- Be your partner in health — we work to bring a better quality of life to our patients.
US gout patients
with flares
with tophi
chronic refractory gout patients
A large percentage of the 9 million patients living with gout are undertreated, relying on short-term or sub-optimal treatments that don’t meet their needs. Our mission is to eliminate the pain of gout with a new era of gout treatment that provides a true solution to reduce flare and tophi.
Litain Yeh
Co-Founder and CEO
